Information - Licensing Action
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Food and Drug Administration
1401 Rockville Pike
Rockville, MD 20852-1448
May 15, 2002
Our STN: BL 103172/5009
Robert L. Garnick, Ph.D.
1 DNA Way
South San Francisco, CA 94080-4990
Dear Dr. Garnick:
Your request to supplement your biologics license application for Alteplase, to revise the package insert to include adding information regarding orolingual angioedema to the Precautions and Adverse Reactions sections, and bolding a statement in the Dosage and Administration section, has been approved.
Please submit all final printed labeling at the time of use and include implementation information on FDA Form 2567. Please provide a PDF-format electronic copy as well as original paper copies (ten for circulars and five for other labels).
This information will be included in your biologics license application file.
--- signature ---
Karen D. Weiss, M.D.
Division of Clinical Trial Design and Analysis
Office of Therapeutics Research and Review
Center for Biologics Evaluation and Research
Last Updated: 5/17/2002
Back to Index
Date created: September 25, 2003